The Biology and Genetics of X-LAG
At a Glance
X-LAG results from an extra copy of DNA at Xq26.3 that includes GPR101, causing excess growth hormone and prolactin in early childhood. Because the change may occur in only some tissues, a negative blood test does not always exclude X-LAG.
To understand X-LAG, it helps to think of the body’s genetic code not just as a set of instructions, but as a complex 3D blueprint [1]. In most cases of growth, the body follows a strict schedule. In children with X-linked acrogigantism (X-LAG), a specific structural change on the X chromosome creates an abnormality in that schedule, leading to the production of far too much growth hormone and prolactin starting in early infancy [2][3].
The Xq26.3 Microduplication and GPR101
The genetic root of X-LAG is a small extra piece of genetic material—a microduplication (copy-number variant)—on the X chromosome at a location called Xq26.3 [4]. This duplicated section contains a gene called GPR101 [5].
In X-LAG, having an extra copy of this gene means the signal stays “on,” constantly driving the pituitary gland to grow and release hormones [6][7].
The “Neo-TAD”: A Proposed 3D Genetic Rewiring
The most recent research suggests that X-LAG is more than just having an extra gene; it may be a disorder of 3D genetic architecture [1]. Our DNA is organized into loops called Topologically Associating Domains (TADs). Think of these as “neighborhoods” where genes and their “on-switches” (enhancers) can talk to each other, separated by boundaries that keep them from talking to neighbors [8].
In a proposed research model, the duplication breaks the boundary of the GPR101 neighborhood. This creates a neo-TAD—a new genetic neighborhood where GPR101 is suddenly exposed to powerful enhancers meant for other genes [1][4]. These enhancers inappropriately activate the gene, forcing the pituitary gland to overproduce growth hormone (GH) and prolactin at massive levels [1][9]. While this model explains many cases, the exact normal function of GPR101 remains an area of research.
Why Boys and Girls Test Differently
The way X-LAG shows up in genetic testing can differ significantly depending on the child’s sex and family history. Because of these complexities, a genetic counselor is essential to explain testing and recurrence risks.
- Germline Duplications: In these cases, the duplication is present in every cell of the body from conception [10]. This makes it very easy to find with a standard blood test [11]. While common in females and familial cases, they can also occur spontaneously (de novo).
- Somatic Mosaicism: The duplication occurred after the egg was fertilized, meaning it is only in some of their cells (like the pituitary or skin) but not necessarily in their blood [5][12]. This pattern is frequently reported in boys.
Because of this, a negative blood test does not rule out X-LAG [5]. If the symptoms strongly suggest X-LAG, specialists may need to test other tissues or use highly sensitive techniques like droplet-digital PCR (ddPCR) to find the duplication [12][11].
Distinguishing X-LAG from “Look-Alikes”
Because rapid growth can have several causes, doctors must distinguish X-LAG from other rare conditions:
| Condition | Primary Genetic Cause | Typical Age of Onset | Key Differences |
|---|---|---|---|
| X-LAG | Xq26.3 duplication | Infancy (0–2 years) | High prolactin; rapid height gain before age 2 [2]. |
| McCune-Albright | GNAS mutation | Early childhood | Often includes café-au-lait spots and bone issues [13]. |
| AIP-Gigantism | AIP mutation | Late childhood/Teens | Usually presents later than X-LAG; often familial [14]. |
| MEN1 | MEN1 mutation | Varies | Involves tumors in multiple glands (parathyroid, pancreas) [15]. |
The Critical Takeaway for Parents
Current expert consensus suggests that young children presenting with confirmed or strongly suspected pituitary gigantism/growth hormone excess should be evaluated for the Xq26.3 duplication [16]. It is not enough to just look for the gene; the lab must look for the structural variant (the extra copy and its boundaries) to give you a definitive answer [4][8]. Knowing the specific “neighborhood” change in your child’s DNA helps the medical team understand exactly why the growth is happening and guide treatment decisions.
Common questions in this guide
What genetic change causes X-LAG?
Which genetic test can detect the X-LAG duplication?
Can a negative blood test rule out X-LAG?
Why might X-LAG testing look different in boys and girls?
How is X-LAG different from McCune-Albright syndrome?
Is the X-LAG duplication inherited?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Was the genetic test performed a chromosome microarray (CMA) or high-density array-CGH rather than just standard sequencing?
- 2.If my child's blood test was negative, should we consider testing other tissues like skin or saliva to look for mosaicism?
- 3.Does the laboratory report specify if the duplication preserves the TAD boundary or includes specific pituitary enhancers?
- 4.How does my child's prolactin level help distinguish this from other conditions like McCune-Albright syndrome?
- 5.Are there any signs of fibrous dysplasia or café-au-lait spots that might suggest a different genetic cause?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism.
Franke M, Daly AF, Palmeira L, et al.
American journal of human genetics 2022; (109(4)):553-570 doi:10.1016/j.ajhg.2022.02.002.
PMID: 35202564 - 2
X-linked acrogigantism syndrome: clinical profile and therapeutic responses.
Beckers A, Lodish MB, Trivellin G, et al.
Endocrine-related cancer 2015; (22(3)):353-67 doi:10.1530/ERC-15-0038.
PMID: 25712922 - 3
A Chinese Case of X-Linked Acrogigantism and Systematic Review.
Liang H, Gong F, Liu Z, et al.
Neuroendocrinology 2021; (111(12)):1164-1175 doi:10.1159/000512240.
PMID: 33049741 - 4
Chromatin conformation capture in the clinic: 4C-seq/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus.
Daly AF, Dunnington LA, Rodriguez-Buritica DF, et al.
Genome medicine 2024; (16(1)):112 doi:10.1186/s13073-024-01378-5.
PMID: 39272130 - 5
Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)-Diagnosis and Management.
Rodd C, Millette M, Iacovazzo D, et al.
The Journal of clinical endocrinology and metabolism 2016; (101(5)):1927-30 doi:10.1210/jc.2015-4366.
PMID: 26982009 - 6
GHRH excess and blockade in X-LAG syndrome.
Daly AF, Lysy PA, Desfilles C, et al.
Endocrine-related cancer 2016; (23(3)):161-70 doi:10.1530/ERC-15-0478.
PMID: 26671997 - 7
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study.
Iacovazzo D, Caswell R, Bunce B, et al.
Acta neuropathologica communications 2016; (4(1)):56 doi:10.1186/s40478-016-0328-1.
PMID: 27245663 - 8
Non-penetrant Xq26.3 duplication involving the invariant TAD border: clinical evidence for the VGLL1 region as the GPR101 pituitary enhancer of X-linked acrogigantism.
Hilditch C, Curtis S, Cotton S, et al.
Pituitary 2025; (28(4)):85 doi:10.1007/s11102-025-01559-4.
PMID: 40684399 - 9
Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism.
Caruso M, Mazzatenta D, Asioli S, et al.
Frontiers in endocrinology 2024; (15()):1345363 doi:10.3389/fendo.2024.1345363.
PMID: 38481440 - 10
Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening.
Iacovazzo D, Hernández-Ramírez LC, Korbonits M
Expert review of endocrinology & metabolism 2017; (12(2)):143-153 doi:10.1080/17446651.2017.1306439.
PMID: 30063429 - 11
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects.
Daly AF, Yuan B, Fina F, et al.
Endocrine-related cancer 2016; (23(4)):221-33 doi:10.1530/ERC-16-0082.
PMID: 26935837 - 12
Genetics of familial acromegaly and pituitary gigantism.
De Sousa SMC, Daly AF
The Journal of clinical endocrinology and metabolism 2026; (111(Supplement_1)):S13-S26 doi:10.1210/clinem/dgag151.
PMID: 41965096 - 13
Burosumab use in fibroblast growth factor-23-mediated hypophosphatemia in McCune-Albright syndrome/fibrous dysplasia.
Alsayed Hasan M, Al Mukaddam M
JCEM case reports 2026; (4(6)):luag086 doi:10.1210/jcemcr/luag086.
PMID: 42100588 - 14
Pituitary gigantism: update on molecular biology and management.
Lodish MB, Trivellin G, Stratakis CA
Current opinion in endocrinology, diabetes, and obesity 2016; (23(1)):72-80 doi:10.1097/MED.0000000000000212.
PMID: 26574647 - 15
Genetics of Acromegaly and Gigantism.
Bogusławska A, Korbonits M
Journal of clinical medicine 2021; (10(7)) doi:10.3390/jcm10071377.
PMID: 33805450 - 16
Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review.
van den Broek MFM, van Nesselrooij BPM, Verrijn Stuart AA, et al.
Frontiers in endocrinology 2019; (10()):837 doi:10.3389/fendo.2019.00837.
PMID: 31920960
This page explains the biology and genetic testing of X-linked acrogigantism for informational purposes only and does not constitute medical advice. Your child’s medical team and a genetic counselor should interpret test results and discuss care.
Get notified when new evidence is published on X-linked acrogigantism.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.